Sign in to continue:

Thursday, January 29th, 2026

Econ Healthcare Reports 128% Profit Surge in H1 FY2025, Declares Interim Dividend




Analysis of Econ Healthcare (Asia) Limited – Net Profit Growth of 128.3%


Analysis of Econ Healthcare (Asia) Limited – Net Profit Growth of 128.3%

Business Description

Econ Healthcare (Asia) Limited is a Singapore-based company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited. The company’s core operations include the management of medicare centres and nursing homes, provision of hospital extension ward management services, homecare services, ambulance services, emergency medical transport services, letting of properties, and investment holding. The company operates primarily in Singapore, Malaysia, and China.

Industry Position and Market Share

Within the eldercare industry, Econ Healthcare faces competition from other private healthcare providers and public institutions. Despite economic and labor challenges, the company has managed to maintain a strong market presence due to its comprehensive service offerings and strategic geographic footprint across key markets in Southeast Asia.

Revenue Streams and Customer Base

Econ Healthcare’s revenue primarily comes from medicare centres and nursing home fees, ancillary fees, and government grants. The customer base includes individual patients, hospitals, and corporate clients. The company’s competitive advantage lies in its integrated healthcare solutions, which include a mix of residential care, homecare, and emergency services.

Financial Statement Analysis

Income Statement

For the six-month period ended 30 September 2024, Econ Healthcare reported a significant revenue increase of 33.7% to S\$32.7 million, driven by higher medicare centres and nursing home fees as well as ancillary fees. The company’s net profit grew by 128.3% to S\$3.6 million, showcasing strong operational performance and effective cost management [[3]] [[4]].

Balance Sheet

As of 30 September 2024, the company’s total assets stood at S\$96.7 million with non-current assets accounting for 68.0% of the total. The company has a strong asset base consisting of property, plant, and equipment, right-of-use assets, and investment property. Total liabilities decreased by 19.5% to S\$49.0 million, indicating improved financial stability [[6]] [[7]].

Cash Flow Statement

Net cash generated from operating activities was S\$9.2 million, reflecting strong cash flow from operations. Investing activities resulted in a net cash inflow of S\$0.2 million, while financing activities saw a net outflow of S\$7.6 million primarily due to repayments of borrowings and lease liabilities [[10]] [[11]].

Dividends

The company declared an interim dividend of 0.48 Singapore cents per share, amounting to S\$1.276 million, compared to 0.23 Singapore cents per share in the previous corresponding period [[37]].

Key Findings

Strengths

  • Strong revenue growth and net profit increase.
  • Diverse revenue streams including government grants, which provide financial stability.
  • Strategic geographic presence in Singapore, Malaysia, and China.
  • Sound financial health with a significant decrease in liabilities.

Risks

  • Economic and labor challenges in the eldercare industry.
  • Potential impacts of regulatory changes on wage costs in Singapore and Malaysia.

Special Actions

The company completed the acquisition of Ambulance Medical Service Pte. Ltd. on 5 March 2024, enhancing its service offerings in emergency ambulance services and medical transport services [[22]].

Investment Recommendations

For Current Investors

Given the strong financial performance and promising growth prospects, it is recommended that current investors hold onto their shares. The company’s strategic initiatives and robust market position suggest continued growth potential.

For Potential Investors

For those not currently holding shares, it is advisable to consider investing in Econ Healthcare (Asia) Limited. The company’s recent financial performance, coupled with its strategic geographic expansion and diversified service offerings, presents a compelling investment opportunity.

Disclaimer

This analysis is based on the financial report for the six-month period ended 30 September 2024. Investors are advised to conduct their own research and consider their financial situation before making investment decisions.


Noel Gifts International Ltd FY2025 Results: No Dividend Declared, Financial Review & Segment Performance

Noel Gifts International Ltd: FY2025 Financial Analysis and Review Noel Gifts International Ltd has released its unaudited financial statement for the full year ended 30 June 2025. This report provides a comprehensive overview of...

SCPLC Q3 2024 Financial Results: 6.8% Operating Income Growth Amid Rising Costs – An Investment Analysis

Analysis of SCPLC Third-Quarter Financial Results (Q3 2024) Business Overview Company: Standard Chartered PLC (SCPLC)Report Date: October 30, 2024Financial Period: Nine months ending September 30, 2024 Core Operations: SCPLC operates as a global banking...

Biolidics Limited Reports Q3 2024 Financial Results and Business Diversification Plans

Biolidics Limited Financial Analysis: Net Profit Decline of 20.7% Biolidics Limited Financial Analysis: Net Profit Decline of 20.7% Business Description Biolidics Limited is a Singapore-based company primarily engaged in the development, marketing, sale, and...